Published in Oncoimmunology on May 02, 2016
Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide. J Immunother Cancer (2016) 0.75
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol (2004) 17.54
CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med (2006) 14.33
T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol (2008) 11.65
The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer (2012) 10.90
A human memory T cell subset with stem cell-like properties. Nat Med (2011) 7.47
Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol (2007) 6.92
Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. J Clin Invest (2003) 6.42
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol (2002) 3.05
Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer (2012) 2.79
Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother (2002) 2.65
The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res (2012) 2.37
Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer (2008) 2.31
Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res (2008) 2.06
Superior T memory stem cell persistence supports long-lived T cell memory. J Clin Invest (2013) 2.06
Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol (2014) 1.77
Impairment of CD4+ cytotoxic T cells predicts poor survival and high recurrence rates in patients with hepatocellular carcinoma. Hepatology (2013) 1.74
Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Invest (2009) 1.73
Cytolytic CD4 cells: Direct mediators in infectious disease and malignancy. Cell Immunol (2010) 1.69
Identification of human regulatory T cells in the setting of T-cell activation and anti-CTLA-4 immunotherapy on the basis of expression of latency-associated peptide. Cancer Discov (2011) 1.52
Cytotoxic human CD4(+) T cells. Curr Opin Immunol (2008) 1.36
Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J Immunol (2004) 1.33
Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. Cancer Res (2009) 1.19
The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination? Cancer J (2011) 1.19
Human CD4+ T cells are predominantly distributed among six phenotypically and functionally distinct subsets. J Immunol (2005) 1.18
The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells. Cancer Res (2009) 1.14
CD4(+)CD25 (+)CD127 (low/-) T cells: a more specific Treg population in human peripheral blood. Inflammation (2012) 1.14
Cancer vaccines. BMJ (2015) 1.07
Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis. J Clin Invest (2014) 1.07
Suppression, subversion and escape: the role of regulatory T cells in cancer progression. Clin Exp Immunol (2013) 1.06
Moving T memory stem cells to the clinic. Blood (2013) 1.02
MHC-peptide tetramers to visualize antigen-specific T cells. Curr Protoc Immunol (2003) 1.02
Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer. Cancer Immunol Immunother (2014) 1.00
Cancer immunology and immunotherapy. Realizing the promise. Introduction. Science (2015) 1.00
Monitoring of NY-ESO-1 specific CD4+ T cells using molecularly defined MHC class II/His-tag-peptide tetramers. Proc Natl Acad Sci U S A (2010) 0.99
A cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma. PLoS One (2012) 0.96
Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001. Oncoimmunology (2012) 0.94
Association of HLA phenotype with response to active specific immunotherapy of melanoma. J Clin Oncol (1992) 0.92
Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer. Clin Cancer Res (2010) 0.90
HLA Class II tetramers reveal tissue-specific regulatory T cells that suppress T-cell responses in breast carcinoma patients. Oncoimmunology (2013) 0.87
LAP+CD4+ T cells are suppressors accumulated in the tumor sites and associated with the progression of colorectal cancer. Clin Cancer Res (2012) 0.86
Increasing the potency of MHC class II-presented epitopes by linkage to Ii-Key peptide. Vaccine (2000) 0.85
Monitoring specific T-cell responses to melanoma vaccines: ELISPOT, tetramers, and beyond. Clin Diagn Lab Immunol (2000) 0.84
AE37 peptide vaccination in prostate cancer: a 4-year immunological assessment updates on a phase I trial. Cancer Immunol Immunother (2013) 0.82
HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer. Invest New Drugs (2013) 0.82
Big bang theory of stem-like T cells confirmed. Blood (2014) 0.81
Prostate cancer vaccines: the long road to clinical application. Cancer Immunol Immunother (2015) 0.81
AE37 peptide vaccination in prostate cancer: identification of biomarkers in the context of prognosis and prediction. Cancer Immunol Immunother (2014) 0.81
Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine. Vaccines (Basel) (2015) 0.80
CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class II epitope hybrid vaccines. Vaccine (2012) 0.79
Vaccination Produces CD4 T Cells with a Novel CD154-CD40-Dependent Cytolytic Mechanism. J Immunol (2015) 0.78
Invariant chain-peptide fusion vaccine using HER-2/neu. Methods Mol Biol (2014) 0.77
A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefit. Cancer Immunol Immunother (2015) 0.77
Short Peptide Vaccine Induces CD4+ T Helper Cells in Patients with Different Solid Cancers. Cancer Immunol Res (2015) 0.76